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Abstract: The underlying ethos of dbGaP is that access to these data by secondary data
analysts facilitates advancement of science. NIH has required that genome-wide association
study data be deposited in the Database of Genotypes and Phenotypes (dbGaP) since 2003.
In 2013, a proposed updated policy extended this requirement to next-generation sequencing
data. However, recent literature and anecdotal reports suggest lingering logistical and
ethical concerns about subject identifiability, informed consent, publication embargo
enforcement, and difficulty in accessing dbGaP data. We surveyed the International
Genetic Epidemiology Society (IGES) membership about their experiences. One hundred
and seventy five (175) individuals completed the survey, a response rate of 27%.
Of respondents who received data from dbGaP (43%), only 32% perceived the application
process as easy but most (75%) received data within five months. Remaining challenges
include difficulty in identifying an institutional signing official and an overlong application
process. Only 24% of respondents had contributed data to dbGaP. Of these, 31% reported
local IRB restrictions on data release; an additional 15% had to reconsent study
participants before depositing data. The majority of respondents (56%) disagreed that the
publication embargo period was sufficient. In response, we recommend longer embargo
periods and use of varied data-sharing models rather than a one-size-fits-all approach.
Keywords: data sharing;
embargo; collaboration
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1. Introduction
In 2003, the National Institutes of Health (NIH) implemented a data sharing policy requiring data
obtained in NIH-supported or conducted genome-wide association studies (GWAS) to be posted to the
database of Genotypes and Phenotypes (dbGaP) or a similar database (NOT-OD-07-088,) [1]. In 2013,
the policy was updated to cover the technological advances in next-generation sequencing so that
whole-exome and whole-genome sequencing studies would also be required to share their data through
dbGaP or similar databases. There are several potential advantages of such a data sharing policy. First,
open access to such complex data reduces barriers and may more rapidly advance science and creativity,
leading to novel discoveries [2]. Second, data sharing maximizes the return on the public investment in
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generating such data, an especially pertinent consideration if one believes that society owns publicly
funded data [3].
These advantages are counter-balanced by practical and ethical concerns in the implementation of
this data sharing policy, and in some cases the NIH has already responded to address issues raised by
the research community. One issue is that specific individuals can be identified based on genomic data
when combined with other publicly available data resources [4–6]. Another study showed that a
surname can be linked with an individual’s genomic data using genealogical databases for descendants
of the Latter-Day Saints founders [7]. Indeed, the U.S. Department of Health and Human Services has
proposed to update the common rule to specifically define biospecimens and genetic data as
identifiable (docket ID number HHS-OPHS-2011-0005; Advance Notice of Proposed Rulemaking
(ANPRM) regarding Human Subject Research Protections). A second issue is that an individuals’ risk
for a specific disease can still be inferred even if known risk allele data is removed. For example,
based on the linkage disequilibrium structure of APOE, as well as available HapMap data, one could
accurately predict Alzheimer’s disease risk for an individual even after removal of the individual’s
APOE genotypes from the analysis [8]. Based on these findings, allele frequencies and other summarized
data were no longer publicly posted on the NIH site. More recently, it was shown that a number of
individuals from the Center for Study of Human Polymorphisms (CEPH) family collection whose
genomes were sequenced as part of the 1000 Genomes project could be identified [9].
Other concerns with the implementation of the data sharing policy have not yet been fully
addressed. First, although the policy allows waivers to the requirement for submission of data to
dbGaP, in practice the implementation of this policy occurs at the institute level, which could allow
inconsistency in how waivers are managed or approved. Much of the need for waivers stems from the
re-use of DNA samples for genetic studies that were collected prior to the discussion of identifiability
and shared databases; thus, appropriate language about possible risks or benefits to the
donors/participants was never included in informed consent forms. Second, a subject’s option to
withdraw from a study is of limited effectiveness once the data is shared in public, as that data has
already been distributed, often cannot be recalled, and therefore may be used for further analysis even
against the will of participants [10]. Third, a publication embargo period was established on many, but
not all, data submitted to dbGaP to recognize the intellectual contributions of the data submitters in
establishing the data resource and provide them with the first opportunity for publication; however, a
violation of the publication embargo has already occurred [11]. In that case, the authors were
reprimanded by both their institution and the NIH, and although the publication was officially retracted
by the journal, it remains available online. Few studies have explored the perceived practical and
ethical concerns of researchers regarding data sharing from GWAS, and whether those concerns
represent significant barriers to the success of dbGaP and other methods of data sharing. To that end,
we conducted a survey of the membership of the International Genetic Epidemiology Society (IGES)
to explore the experiences of researchers with dbGaP. IGES is a scientific society concerned with ―the
study of genetic components in complex biological phenomena‖ [12]. IGES members include
geneticists, epidemiologists, statisticians, mathematicians, biologists, related biomedical researchers
and students interested in research on the genetic basis of diseases, complex traits, and their risk
factors. This survey population may provide generalizable insights for several reasons. First, the IGES
membership is involved in human genetic research and includes scientists who have contributed data
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to dbGaP. Second, IGES members, especially those who are developing novel statistical methods and
genetic epidemiological techniques, are among the researchers most interested in obtaining data from
dbGaP. Finally, the practical barriers and perceived ethical challenges experienced by IGES members
with dbGaP use for genome-wide association (GWA) data have relevance for future sharing of whole
exome (WES) and whole genome sequencing (WGS) data.
2. Experimental Section
2.1. Survey Design and Implementation
Members of the IGES Ethical, Legal, and Social Issues (ELSI) committee designed the survey
instrument (supplemental materials). The committee is a multidisciplinary group generally interested
in current ELSI issues as they relate to genetic epidemiologists. Committee members come from a
variety of backgrounds and have varied research interests ranging from biology, medicine, statistical
genetics, and epidemiology, to bio-ethical theory and law. Questions, both multiple choice and
free-text, covered domains including demographics, past application for research funding, contribution
of data to dbGaP, access of data through dbGaP and other similar databases, and avoidance of the data
sharing policy. We implemented the survey, containing 44 questions, on SurveyMonkey® [13].
Members of the IGES ELSI committee pilot tested the survey to check the skip patterns to the questions
and ease of use; however, we did not pilot test the survey with external reviewers to assess the readability
or comprehension of the survey questions. All IGES members were invited to complete the survey by
email through the IGES membership listserver. We sent two reminder emails, as well as a post to the
―Friends of IGES‖ Facebook page. No incentive was given for participation in the survey, and no
identifying information (e.g., IP address) was obtained from the survey participants. The survey was
open for response from October to November of 2010.
2.2. Data Analysis
We downloaded a dataset containing all participant response data from SurveyMonkey as an Excel
file. We computed descriptive statistics and statistical analyses using SPSS version 19 (IBM Corp.
Armonk, NY, USA)). Percentages are reported based on the number of valid responses for each
question. Analyses of categorical data were conducted using chi-square statistics. Eight questions were
open-ended; responses for those could be entered into a box that could contain a brief paragraph.
Eleven questions provided an ―other‖ category as a response; the respondent could then specify an
alternative response. We analyzed data from open-ended questions by looking for common themes.
Responses were first separated into the two major thematic categories that corresponded to either
common practical or ethical concerns. These responses were then further analyzed to identify more
specific areas of concern.
3. Results and Discussion
A total of 187 individuals started the survey; 175 out of 643 IGES members completed it (Table 1),
resulting in a response rate of 27%. Most of the survey respondents (77%) were ―Regular‖ (i.e.,
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not student) IGES members. The distribution of survey respondents by continent was roughly
equivalent to the overall distribution of IGES membership (Table 1).
Most of the survey respondents work in academic or university environments (Table 2). There was
a fairly uniform distribution of respondents across time spent in their current position, with the
exception that fewer people had spent 11 to 15 years at their current position. Most of the faculty
respondents had applied to the NIH for research funding (83%), regardless of whether they worked in
North America (Table 2).
Table 1. Demographics of survey respondents compared to overall IGES membership.
Students
Regular
Total
Continent / region
United States
Canada
Europe
Australia, New Zealand, and Other
a

Survey Respondents a
33 (18%)
147 (82%)
175

Data shown as absolute frequencies (% of total).

138 (74%) b
39 (21%)
9 (5%)
b

IGES Overall Membership a
146 (23%)
497 (77%)
643
428 (67%)
37 (6%)
123 (19%)
55 (8%)

These two categories are combined because the survey

only asked whether respondents worked in North America, so that data were not identifiable.

Table 2. Survey respondents’ position characteristics.
Characteristic
Type of organization
Academic or university
Government agency
Hospital
Research Institute
Industry
Length of time in current position
< 3 years
3 to 5 years
6 to 10 years
11 to 15 years
> 15 years

N (%)
129 (72%)
17 (9%)
11 (6%)
22 (12%)
1 (0.5%)
52 (29%)
37 (21%)
41 (23%)
15 (8%)
35 (19%)

3.1. Data Access
Of all respondents, 43% (N = 80) reported accessing data from dbGaP at least once (Table 3).
When asked, ―How long did it take to complete the application and receive the data the first time you
applied?‖, 37.5% (N = 30) stated it took less than 3 months, and an additional 37.5% (N = 30) indicated
that it took 3–4 months. Among those who reported applying for data more than once (N = 30),
responses to the question, ―How long did it take to complete the application and receive the data the
most recent time you applied?‖ did not differ noticeably. When asked how much they agreed/disagreed
that the process of requesting data from dbGaP was easy, many respondents (32%) agreed.
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The duration of time it took to complete application and receive the data was associated with whether
the respondent agreed that the dbGaP application process was perceived as easy (p = 0.015).
We also asked what sort of ethics board approval, if any, was required when accessing dbGaP data.
Sixteen percent (N = 13) of individuals reported full ethics board approval, 38% (N = 30) reported an
expedited review, 20% (N = 16) reported that their institution waived the requirement for ethics board
approval, and 15% (N = 12) reported that their institution did not require ethics board approval
(Table 4). Thus, ethics board approval requirements were widely variable across institutions; this did
not differ significantly by the type of institution (p = 0.153) or by continent (p = 0.312) (data not
shown). The type of IRB approval needed was not associated with whether the respondent agreed that
the dbGaP application process was perceived as easy (p = 0.239).
Table 3. Attitudes towards dbGaP access issues a,b.

The process for
requesting data from
dbGaP was easy
It was easy to find a
signing official

Strongly
Agree

Agree

Disagree

Strongly
Disagree

Undecided /
Don’t Know

Missing / No
Response

2 (3)

23 (29)

25 (31)

14 (18)

9 (11)

7 (9)

29 (36)

23 (29)

7 (9)

7 (9)

1 (1)

13 (16)

a

Numbers are absolute frequencies (%);
responded to this question (N = 80).

b

Only individuals who reported requesting data from dbGaP

Table 4. IRB application experience for individuals requesting dbGaP data.
Response

N (%) a

Yes, I had to go through full-board review

13 (16)

Yes, I had to go through an expedited IRB (or equivalent) review

30 (38)

No, the IRB (or equivalent) waived the requirement for approval, or the study

16 (20)

was considered exempt
No, my Institution does not require me to apply for IRB (or equivalent)

12 (15)

approval to obtain and analyze data from dbGaP
Missing / no response

9 (11)
a

Data shown as (absolute) frequencies (%), N = 80.

An ―institutional official‖ needs to sign a researcher’s application for dbGaP data, a concept that
may not be well-defined for organizations that do not receive funding from NIH. Most individuals
(65%) either agreed or strongly agreed that it was easy to identify a signing official. However, the title
of the signing official varied widely. In the free-text field where respondents listed the title of the
signing official, 12 individuals reported a title of someone in a research administration office,
six individuals reported the title of an academic head or scientific director, three individuals reported a
―director‖ position that did not appear to fit into a research office or academic head, and two
individuals reported getting the signature of the president of the university. The ease of identifying a
signing official differed significantly by type of institution, with more people in research institutes
reporting difficulty with identifying the signing official (p = 0.003, data not shown). This issue was
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also associated with continent, with more Europeans reporting problems than North Americans
(p = 0.029, data not shown); five European respondents (36%) either agreed or strongly agreed that it
was difficult to find a signing official, and four individuals at research institutes (44%) also agreed or
strongly agreed it was difficult to find a signing official. The ease of identifying a signing official was
associated with whether the respondent agreed that the dbGaP application process was perceived as
easy (p = 0.005).
Only 19% of individuals (N = 15) reported contacting the original data contributors regarding
questions about the data.
3.2. Data Contributors
Twenty-four percent (N = 45) of all respondents reported being the principal investigator or
co-investigator on a study that contributed data to dbGaP. We note that dbGaP submission requires the
local IRB to certify consistency with laws and regulations, which can vary by state or country,
and with the content necessary to be provided in informed consent documents, which can vary by
study as well as by state or country. Of the respondents who contributed data to dbGaP, 31% (N = 14)
reported local IRB restrictions on data release, and 31% (N = 14) reported that they had to reconsent
study participants (seven individuals answered ―yes‖ to both questions). Of the individuals who did
reconsent their study participants, at least 32% did not inform them of the risk of being identified from
genotype or phenotype data (Table 5).
Table 5. Information about depositing data to dbGaP from 45 responders.
Questions and Responses
For how many studies have you deposited data into dbGaP?
1
2
3
5
Missing / no response
For any of the studies that you contributed to dbGaP, did your IRB
(or equivalent) put any restrictions on data release?
Yes
No
Not sure
Missing / no response
For any of the studies that you contributed to dbGaP, did you reconsent the
research participants in order to deposit the data on dbGaP
Yes
No
Not sure
Missing / no response
When you reconsented individuals, did you inform individuals about the
potential of being identified from their genotype or phenotype data?a
Yes
No

N (%) a
28 (62)
12 (27)
1 (2)
2 (4)
2 (4)

14 (31)
21 (47)
9 (20)
1 (2)

14 (31)
24 (53)
6 (13)
1 (2)

6 (43)
3 (21)
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Questions and Responses
Not sure
How much do you agree with the following statement: The embargo period
was sufficient to perform the analyses that I wanted to do?
Strongly agree
Agree
Disagree
Strongly disagree
Undecided
Too early to determine
Missing / no response

N (%) a
5 (36)

1 (2)
9 (20)
12 (27)
13 (29)
6 (13)
3 (7)
1 (2)

a

Denominator for this question is N=14, the number of individuals who reconsented their subjects; b Data
shown as (absolute) frequencies (%)

While seven individuals requested a waiver from submitting data to dbGaP, three of these
individuals did not get the waiver granted. The four successful requests for waivers included the
following justifications: a foreign study population (N = 1), ―no consent‖ or ―not able to reconsent‖
(N = 2), and ―sensitive topic‖ (N = 1). The three unsuccessful waiver requests provided justifications
that included ―would require reconsent‖ (N = 2) and ―participating American Indian tribes would not
agree to broad data sharing‖ (N = 1).
Our final question for data contributors was whether the publication embargo period was sufficient
to perform the desired analyses. The majority of respondents (56%) either disagreed or strongly
disagreed that the embargo period was sufficient (Table 5). Two individuals reported in a free-text
field that data they had submitted to dbGaP, had been downloaded and analyzed by another group and
the findings published before the embargo period was over.
3.3. Alternatives to Depositing Data in dbGaP
Next, we asked a series of questions to get a sense of whether the current data sharing policy limits
opportunities for research, and, if so, what are the perceived barriers. Eleven percent of all respondents
(N = 21) reported applying for funding elsewhere to avoid the NIH data sharing policy. Fourteen
percent (N = 26) of individuals decided not to apply for NIH funding specifically because of the data
sharing policy. Fourteen people answered ―yes‖ to both questions. Several reasons were given for this
(Table 6). The most prevalent response was that the consent form or local IRB would not allow this
type of data sharing (N = 16), or it would be ―not legally possible because of requirements in country‖
(N = 12); six people responded that they ―do not trust the system of data sharing‖.
Table 6. Reasons given for not applying for NIH funding because of the data
sharing policy.
Reason
It would not be legally possible to deposit the data in dbGaP according to country’s
(or institutional) requirements

N*
13
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Reason
The procedure was too complicated
The consent form would not allow broad data sharing
Did not trust system of data sharing
The data sharing policy is ―not in agreement with my personal ethical opinions‖
Subjects deceased and cannot be reconsented
Inability to require IRB approval by data requestors
Vulnerable population
Data collected from other countries
Social responsibility
*

N*
3
16
6
1
1
1
1
1
1

Respondents may have selected more than one relevant response, so only absolute frequencies are shown.

3.4. Future Implications
We asked whether respondents foresee additional problems with depositing/sharing WGS data;
only 32% (N = 60) agreed. Respondents were then given the opportunity to describe their own
perceptions of these specific problems through an open-ended question. These qualitative responses
are not meant to be generalized or representative, but do provide some insight into the types of
concerns researchers may have about interfacing with dbGaP and other large genomic databases.
Responses to this question fell into two primary thematic categories: practical barriers associated with
the management and ―usability‖ of the database, and ethical concerns regarding contributing data and
the future use of DNA and RNA sequence data. However, within each of these categories, respondents
were varied in their actual concerns.
First, with regard to the practical challenges of dbGaP, some respondents were skeptical of the
sustainability of dbGaP itself given concerns about the ability of the system to store and manage such
large datasets while making them easily accessible to researchers. Others expressed more specific
concerns about the ability of researchers to interface with dbGaP for purposes of both transferring data
to the database and enabling researchers to access the data for future research. One researcher wrote
that (s)he perceived ―data transferral with these large datasets will be highly problematic‖ while
another voiced concerns over the amount of ―pre-processing and standardization‖ needed for large
datasets. Additionally, respondents expressed concerns regarding the utilization of data in dbGaP for
future studies, including a number of researchers that indicated apprehension about the time required to
download larger datasets and others who felt that the user interface was hard to use or ―cumbersome‖.
Lastly, a few respondents said that they would question the quality of raw DNA or RNA sequence data
from dbGaP in light of their concerns about the ability of dbGaP to effectively manage and usefully
transfer to researchers the large volume of information associated with sequence data.
In addition to these practical issues, respondents identified ethical and social implications of
contributing and using data associated with dbGaP. Three interconnected concerns were mentioned:
(i) the problem of increased identifiability of study participants, (ii) the impact of increased identifiability
on the consent process, and (iii) potential difficulties in subject recruitment due to (i) and (ii).
The problem of identifiability is amplified by the ability to mine DNA sequence data for
―rare variants‖, potentially making an individual or families more identifiable. One respondent thought
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the contribution of sequence data to dbGaP would compromise the ability of researchers to assure the
privacy and confidentiality of study participants, while others felt that participants may worry about
their genetic data being used for the identification of deleterious mutations without their knowledge
or permission.
An increased risk of identifiability (and concomitant loss of confidentiality) can be expected to have
an impact on the consent process. One respondent asked, ―How is the consenting of patients for this
type of data release going to be handled? Will a general data release statement be sufficient as it was
for SNPs? How do we define informed consent?‖ Another individual discussed fears that contributing
whole genome or exome sequence data to dbGaP presents ―deeper issues of identification‖ and raises
questions as to ―whether we can truly adequately consent people for this type of data sharing‖.
Lastly, one researcher expressed a further worry that requirements to contribute data might hurt
subject recruitment due to a ―possible reluctance of some to participate in studies‖. If the sharing
requirement for sequence data has a chilling effect on subject recruitment, it would undermine the
potential benefits expected from the policy.
4. Conclusions
In summary, many respondents to our survey (34%) agreed that they perceive the application
process for dbGaP data access as easy and 75% were able to receive data in less than five months.
The considerable effort put into the development of the dbGaP system [11] has resulted in a few
remaining challenges. These opportunities for improvement of the system, including simplifying the
approach to identify a ―signing official‖ and management of large datafiles, are modest when
compared with the challenges of initiating new data collection, which can take years. On the other
hand, researchers who contribute data to dbGaP face many challenges, primarily local IRB restrictions,
the need to reconsent individuals and inform them about potential risks of identifiability, and the short
length of the publication embargo period. Significant opportunity for improvement in the implementation
of the NIH data sharing policy is still possible from the perspective of data contributors. Further, a mixed
approach to data sharing models—including consortiums and workshops—may also alleviate some of
these challenges.
4.1. Issues for dbGaP Access and Use
The race to publish on one’s own data as it relates to the publication embargo remains an issue.
In our relatively small dataset, two individuals reported that data recipients from dbGaP published
before the embargo period was over. As stated by Kaye et al. [2], ―no one wants to be part of a system
in which they feel that someone else can take advantage of their contributions.‖ Furthermore,
Kaye et al. [2] argue that working against deadlines is not consistent with a productive climate.
On the other hand, others argue that without a deadline, researchers hold their data indefinitely without
analyzing and publishing, so a deadline is a strong motivating factor. We recommend that the
publication embargo policy be reviewed to enable more time for the data contributors to analyze and
publish on their own data, which would provide greater protection and recognition of the intellectual
contributions of the data contributors and their expertise with the dataset. Additionally, we recommend
that enforcing the publication embargo be a shared responsibility between data requestors and others—
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journal reviewers, journal editors, and the NIH—who can find proactive solutions to identify potential
violations before they occur.
In our study, a minority of dbGaP users (<20%) contacted the data collectors, though this was
encouraged by the coordinators of dbGaP, as evidenced by the prominent publication of contributors’
contact information. Krawczak et al. [14] point out that the bottleneck in generating high quality
genetic epidemiological data is mostly in the recruitment and phenotyping of subjects, not in the
genotyping. Those who collected the data may be aware of subtleties that can improve analyses or
interpretation. Thus, we encourage increased interaction with the data collectors and formal
recognition of their efforts. Also, we encourage data collectors to be responsive to the collaborative
attempts of secondary data analysts. Depending on the extent of collaboration with the data collectors,
recognition of their efforts may be made via co-authorship or in the acknowledgments section of the
paper. A recent editorial published in Nature Genetics also suggested the use of citable data
management plans as another method to acknowledge the data collectors [15].
4.2. Ethical Implications for Access and Contribution
We observed a great deal of variability in local IRB requirements for receiving dbGaP data.
One possibility is that we observe this variation because there are different requirements for ethics
board approval depending on the dbGaP dataset, and it is a limitation of our survey that we did not
distinguish which dbGaP datasets the survey respondents had requested. However, this variation
among respondents regarding their IRB requirements for dbGaP access may be concerning for
contributors to dbGaP, because it may imply variability among IRBs in the understanding of genetic
databases and the implications for human subject protection. As recently noted by OHRP in the
Advanced Notice of Proposed Rule Making (ANPRM) for revision to the Common Rule [16],
this variation is a broad concern, and is not limited to genetic research. McGuire and Gibbs [17] state
that, in their experience, the consent process for most disease-specific genetic research is not protective
for broad genomic data sharing because privacy risks are not stated. McWilliams et al. [18] found that
IRB review of genetic epidemiology studies was inconsistent across local IRBs. More recently,
Lemke et al. [19] found wide diversity among IRB members in the specific ethical implications
inherent in genetic data, such as the risk of identifiability, the need for reconsent, clarity in NIH data
sharing guidelines, likelihood of individuals being identified from genetic data, and likeliness of harm.
The issues of re-consent and warning participants of the risks of identifiability are challenging because
these risks are unknown. As pointed out by Kaye et al. [2], ethics committees cannot exert their
mandates on recipients of data from other institutions. A potential solution for dbGaP is to require data
requestors to obtain IRB approval from the IRB where the data were collected through Data
Use Limitations [20].
4.3. The Consortium Model
A complimentary model to public data sharing, which has been quite successful, is the formation of
large consortia in which data from different projects are combined, and a variety of researchers with
different expertise in aspects of phenotyping and methodology collaborate to jointly analyze their data.
The consortium data sharing model may be particularly advantageous in situations where potential data
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contributors experience limitations because of local IRB restrictions or a need to reconsent study
participants. Often, data are meta-analyzed in order to gain statistical power, and numerous consortia
have published on novel loci identified using this model of data sharing. Examples include the
CHARGE consortium [21], the CARe consortium [22,23], the Alzheimer Disease Genetics Consortium
(ADGC) [24], CGASP [25], other smoking consortia [26,27], LLAS1 and LLAS2 [28,29], and the
Electronic Medical Records and GEnomics (eMERGE) consortium [30].
Data are not shared as widely under this model, and large consortia have challenges, some of which
are in common with the challenges of data sharing through dbGaP. The experiences of consortia with
their internal data sharing and authorship policies may vary widely, and enforcement of those policies
may be delicate because of relationships among collaborators. Often (but not always) large consortia
do not have dedicated research funding to support additional data analysts, data coordinating centers,
or common genotyping core facilities. The activities of the consortium must be conducted using
resources on existing, potentially smaller-budget grants. Data transfer within consortia may also have
logistical difficulties, such as the amount of time for transferring large scale sequencing data or
the need for pre-processing and standardization, that are similar to the challenges for data sharing
through dbGaP.
However, there are advantages of the consortium model. First, the research teams are working
together, so any questions about how the data were collected or how phenotypes were defined can be
resolved. Second, collaborating groups work directly with the IRBs of the institutions where the data
were collected. In contrast, dbGaP data requestors frequently obtain IRB approval from their local IRB
rather than the IRB responsible for the approval of the study for collecting data. Consortia deal with
this issue directly by writing memoranda of understanding, and additionally, investigators add each
other to their IRB protocols.. Third, as discussed above, there is direct acknowledgment of the data
collectors via co-authorship. One recommendation to further enhance collaboration in the same spirit
of the NIH data sharing policy is to expand research funding for consortia to support the activities of
research teams. Indeed, some survey respondents implied support for this model when answering the
open-ended questions throughout the survey. Further, the consortium model could be strengthened by
developing a mechanism, perhaps through dbGaP, to publicize information about existing consortia so
that interested researchers could contact members of those consortia to develop collaboration.
One reason for the development of dbGaP was to make data available for the purposes of
methodology development. The Genetic Analysis Workshop (GAW) is another enormously successful
model to stimulate collaboration among scientists interested in methodological questions. The GAW
addresses questions about the robustness of analytical approaches for genetic data and serves as a
forum for discussing new methods of analysis. The GAW has been ongoing since 1982 [31], and is
supported through a grant from the National Institute of General Medical Sciences. The most recent
GAW meeting in 2012 included 184 participants from 14 countries [32]. For each meeting, specific
datasets are selected for analysis by an advisory committee, and are distributed to interested
researchers about six months prior to the meeting. The workshop paradigm is particularly suited to
advances in methodology development since all individuals are working on the same dataset(s),
focusing on the same set of methodological questions, and meeting together to discuss results and learn
from one another. Thus, we recommend additional funding for similar workshops.
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4.4. Implications for Future Studies
The issues that have been identified for sharing GWAS data through dbGaP may be amplified when
sharing WGS data. WGS datafiles are vastly larger than those from GWAS. Genetic epidemiologists
have encountered problems in downloading 1000 Genomes data, and such problems will be intensified
many-fold with deep coverage sequence data. Thus, effective sharing of sequence data may be limited
to individuals with considerable computational resources, although this may change as computational
technology advances. In addition, there is an ongoing debate about the identifiability of subjects from
GWAS, WES or WGS data, and these concerns were raised by our survey respondents. Malin et al. [33]
detail the conditions for identifiability, which include whether the data are ―distinguishing‖ (genome
data fall into this category) and the availability of a ―naming resource‖. Thus, the risks of
identifiability may vary widely in human genetic studies and should be considered as these large
datasets are made available. Furthermore, while clinically relevant information in GWAS data is
limited to sex chromosome anomalies and a small number of disease risk SNPs [34], an added
complexity of WGS data is the significantly greater potential of discovering ―incidental findings‖ of
well-characterized risk variants [2,34–36]. If in the original consent form the duty to report incidental
findings is mentioned, complying with this obligation may be challenging when secondary data
analysts make these discoveries. As the technology to create WGS data moves forward, there will be a
great need to develop statistical methodologies to analyze these data, so the motivation to share these
data is high in spite of the logistical concerns. Further discussion of the ethical implications of
identifiability and incidental findings must precede the development of policies for sharing WGS data.
4.5. Limitations
There are some limitations of this survey and its analysis. First, the survey was only administered to
IGES members, and thus may not be generalizable to all users of dbGaP. Geneticists with other
specializations also have accessed or contributed to dbGaP, and so our results may not reflect their
experiences. Second, the response rate to the survey was quite low (27% of IGES members), and it is
unknown why a larger percentage of the IGES membership did not respond to the survey. Because of
the low response rate, the study findings are susceptible to bias if individuals with particularly good or
bad experiences preferentially responded to the survey. Also, we did not pilot test the survey questions
with external reviewers to assess the readability or comprehension of the survey questions, so we do
not know whether or not some respondents had difficulties responding to the questions. Finally, there
are a number of topics that were not included in our survey, such as experiences with consortia, how
long it takes to complete specific aspects of the application process including identifying the signing
official, how data recipients used the data, and what were the perceived benefits of the policy.
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